The Quotes are Powered By Forexpros, the Forex, Futures, and Stock Markets Portal.

BioInvent granted US patent for the F.I.R.S.T.™ antibody screening technology

Monday, 11 November 2013
BioInvent International AB (OMXS: BINV) today announces that it has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T.™.

Traditional drug discovery methods involve the identification of drugs candidates that bind to known disease targets. The F.I.R.S.T.™ technology is a novel and unique discovery method, which allows for antibodies and disease targets to be identified simultaneously.

BioInvent has used F.I.R.S.T.™ successfully in several proprietary discovery projects and offers F.I.R.S.T.™ as well as traditional antibody discovery screening to commercial partners.

“With billions of binders available in the libraries and state-of-the-art in vitro and in vivo cancer and immunological assays, we can discover antibodies with the very best properties for onward development.” Said Björn Frendeus, VP
Based on press release – scancomark.com

Did you spot any error(s) or had any problem with the above article. Please contact us